Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Physical Review Letters|November 26, 2016
Role of Excited States In High-order Harmonic GenerationS Beaulieu, S Camp, D Descamps, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
JAMA Dermatology|October 30, 2024
Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring IndexKhaled Ezzedine, Ahmed M Soliman, Heidi S Camp, et al.
Rheumatology (Oxford, England)|December 14, 2020
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPYVibeke Strand, Namita Tundia, Alvin Wells, et al.
Hormones & Cancer|June 11, 2020
Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone TherapyRobert Dembinski, Vishnu Prasath, Carisa Bohnak, et al.
The Breast Journal|June 4, 2014
Management of positive sub-areolar/nipple duct margins in nipple-sparing mastectomiesMelissa S Camp, Suzanne B Coopey, Rong Tang, et al.
Journal of Cardiothoracic and Vascular Anesthesia|September 6, 2011
Pilot implementation of a perioperative protocol to guide operating room-to-intensive care unit patient handoffsMichelle A Petrovic, Hanan Aboumatar, William A Baumgartner, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
The Journal of Gene Medicine|March 15, 2006
Immune responses to AAV in a phase I study for Canavan diseaseS W J McPhee, C G Janson, C Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 2007
Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitorsHongyu Zhao, Michael D Serby, Harriet T Smith, et al.
Pageof 14